More data sought on Arcoxia

As expected, the FDA has told Merck that it will need to provide more safety data on Arcoxia before it can be approved as a successor to Vioxx, its Cox-2 inhibitor pulled after being linked to scores of heart attacks and strokes. Merck said this morning that it will continue with two late-stage trials of Arcoxia, including one two-year trial. Merck says that it will provide new data from the Phase III trials in 2006.

- read this article from the AP for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.